Skip to main content
OpenTrials
Completed

NCT Number: NCT02637427

Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures

The purpose of this study is to evaluate prophylactic fresh frozen plasma transfusion in patients with moderately elevated international normalized ratios (INR) prior to undergoing an invasive procedure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Johns Hopkins University, The Johns Hopkins Hospital, Baltimore, Maryland, United States

Loading trial locations.

About this study

Fresh frozen plasma is used very frequently in the US. Many plasma transfusions are given prior to a procedure in order to correct perceived bleeding risk, yet there is little evidence to support that use of plasma reduces bleeding. There has never been an adequately powered trial to establish the efficacy of plasma and document the risks. This pilot study will evaluate the feasibility of conducting a research protocol that will lead to a large scale clinical trial designed to evaluate the treatment effectiveness of prophylactic plasma transfusion in patients with moderately elevated INRs prior to undergoing an invasive procedure outside of the operating room.

Study subjects will be randomly allocated to either receive either plasma transfusion prior to the procedure, or to no treatment. Study outcomes will be compared between the two study arms. Recruitment rates, protocol adherence, and rates of study outcomes will be assessed to determine the feasibility of the large scale trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • INR level between 1.50 and 2.50 inclusive
  • undergoing an invasive procedure at the bedside, endoscopy laboratory, or in radiology

Exclusion criteria

  • undergoing a surgical procedure in the operating room;
  • active bleeding;
  • undergoing a procedure involving or proximal to the central nervous system or spinal cord;
  • cardiac catheterization,
  • using 4 factor plasma concentrates
  • using systemic heparin/heparinoid therapy, direct factor X inhibitors and other anticoagulants for which plasma will not correct prolonged INR;
  • platelet count less than 50,000/ul,
  • congenital coagulation disorders;
  • acquired disorders (i.e., lupus anticoagulant) for which plasma will not correct the disorder;
  • women who are pregnant and;
  • unwillingness to consider blood transfusion.

Treatment and study plan

Fresh frozen plasma transfusion

Biological

Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)

Primary outcomes

  1. Change in Hemoglobin Level

    Time frame: within 2 days post procedure

    Change from pre-procedure hemoglobin to lowest within 2 days after procedure

Secondary outcomes

  1. Number of Red Blood Cell Transfusions

    Time frame: within 2 days post procedure

    Differences in number of units of red blood cell transfusions between the two study arms

  2. Number of Participants With Transfusion Associated Cardiac Overload (TACO)

    Time frame: within 2 days post procedure

    Difference in rates between the two study arms

  3. Number of Participants With Transfusion Related Acute Lung Injury (TRALI).

    Time frame: with 2 days post procedure

    Difference in rates between the two study arms

  4. Number of Participants With Major Bleed

    Time frame: with 2 days post procedure

    2g/dL or greater fall in hemoglobin level

  5. Change in International Normalized Ratio (INR) Level Post Procedure

    Time frame: day of procedure

    Change from pre-procedure INR level

  6. Change in INR Level Day 1

    Time frame: day 1 post procedure

    Change from pre-procedure INR level

  7. Change in INR Level Day 2

    Time frame: day 2 post procedure

    Change from pre-procedure INR level

  8. Mortality (Number of Participants)

    Time frame: in-hospital up to 7 days

    Death

  9. Number of Participants With Infection

    Time frame: within 2 days post procedure

    Pneumonia or blood stream infection

  10. Number of Participants With ICU Admission

    Time frame: within 2 days post procedure

    new admission to the intensive care unit

Sponsors and collaborators

Lead sponsor

Rutgers, The State University of New Jersey

Other

Collaborators

  • Johns Hopkins University
  • National Heart, Lung, and Blood Institute (NHLBI)
  • University of Pittsburgh
  • University of Washington

Registry information

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Dec 22, 2015
Registry last updated
Aug 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.